Clinical trial · no report yet · Phase 2
NCT02292758
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
- NCT02292758 ↗
- Completed
- Academic and Community Cancer Research United
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 11 | |
| Podcasts | 4 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Colorectal Adenocarcinoma; RAS Wild Type; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Bevacizumab; Cetuximab; Irinotecan; Laboratory Biomarker Analysis; Placebo
- Arms
- Arm I (cetuximab, bevacizumab, irinotecan) · Experimental
- Arm II (cetuximab, placebo, irinotecan) · Active comparator
- Enrollment
- 36
- Primary outcomes
- Progression-Free Survival (PFS)
- 6-month and 12-month Progression-free Survival (PFS) Rates
- Sponsor
- Academic and Community Cancer Research United with National Cancer Institute (NCI)
- Start
- Dec 12, 2014
- Primary completion
- Mar 20, 2019
- Results posted
- Yes
- Registry record
- NCT02292758 · updated Jan 31, 2022
Publications
linked from the registry- Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist. 2022 Apr 5;27(4):292-298. doi: 10.1093/oncolo/oyab025. PubMed 35380713